DAWEX/CEA
28.5.2024 09:31:30 CEST | Business Wire | Press release
Dawex and CEA today announced that they have signed a partnership agreement to create a joint Research & Development Laboratory. Aiming at conceiving and developing technological solutions to catalyze truly impactful innovations in the field of data ecosystem, the collaboration between the CEA and Dawex will feed responses to global industry challenges to shape a more sustainable & resilient future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528953935/en/
The creation of secure, trusted and interoperable data ecosystems and data spaces has become crucial in fostering trusted artificial intelligence and realizing a sustainable and digital society. Data exchange and data circulation are at the forefront in boosting transformative solutions such as Generative AI, while pushing the boundaries of innovation thanks to Privacy Enhancing Technologies integration —ultimately making such disruptive technologies accessible to customers.
Since its inception, Dawex has been investing in Research & Development, in order to bring the perfect conditions for secure, trustworthy, sovereign and compliant data exchange. Dawex will bring to this collaboration its extensive and proven expertise in secure data exchange, data governance, interoperability, standards & norms. Through active engagements in developing the most advanced data exchange solutions and contributing to regulations, norms & de facto standards, Dawex has been demonstrating its leadership as a strategic market player, notably by powering the largest number of European data spaces.
The CEA participates in accelerating industry transformation with programs on the factory of the future, digital twins, artificial intelligence, and digital trust. It ultimately contributes to building a powerful innovation ecosystem guided by the values of social and environmental responsibility.
“Innovation and Research have been in Dawex DNA since Day-1. We are committed to advancing data exchange matters and address forward looking data challenges, delivering the most sophisticated data exchange technology” said Fabrice Tocco, co-CEO at Dawex. “We are extremely happy to collaborate with the CEA and co-innovate to bring the next-generation innovations that will transform data exchange,” concluded Mr Tocco.
”Data exchange plays a major role in the industry transformation that France and Europe are facing today. This leads CEA to partner with Dawex as a leading company in the field of data exchange and data ecosystems”, declared Alexandre Bounouh, CEO of CEA List institute. “Creating together a common R&D laboratory will enable us to bring thorough and trusted digital solutions to the industry with one objective in mind: to accelerate transitions and among them energy & climate ones. We are delighted to pursue this ambition with Dawex”.
About Dawex
Dawex is the leader in Data Exchange solutions to distribute or share data products, with trust, for any business case, in compliance with data regulations. With Dawex Data Exchange technology, organizations create data ecosystems and data spaces such as Corporate Data Hubs, Industry Data Hubs and Data Marketplaces to address economic, environmental and decarbonation challenges. At the invitation of the United Nations, Dawex joins the Data expert group of the United Nations Environment Program. Awarded Technology Pioneer by the World Economic Forum, Dawex is also the initiator of an international standardization program on Trusted Data Transaction. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
About CEA
The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security.
As the world's leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry. More information: https://www.cea.fr/english
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528953935/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom